Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kolitz, Sarah ^a   Hasson, Tal ^b   Towfic, Fadi ^a   Funt, Jason M ^a   Bakshi, Shlomo ^b   Fowler, Kevin D ^a   Laifenfeld, Daphna ^b   Grinspan, Augusto ^b   Artyomov, Maxim N ^a   Birnberg, Tal ^b   Schwartz, Rivka ^b   Komlosh, Arthur ^b   Hayardeny, Liat ^b   Ladkani, David ^b   Hayden, Michael R ^b   Zeskind, Benjamin ^a   Grossman, Iris ^b  

^a Immuneering Corporation   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GLATIRAMER; MATRIX METALLOPROTEINASE; MESSENGER RNA; TRANSCRIPTOME;

CELL LINE; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MONOCYTE; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

CELL LINE; CHEMOKINES; GLATIRAMER ACETATE; HUMANS; MATRIX METALLOPROTEINASES; MONOCYTES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTOME; UP-REGULATION;

EID: 84930208452     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10191     Document Type: Article

References (52)

1. Conner, J. B., Bawa, R., Nicholas, J. M. & Weinstein, V. in Handbook of Clinical Nanomedicine - From Bench to Bedside (Pan Stanford Publishing, 2014).
2. Arnon, R. & Aharoni, R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl. Acad. Sci. 101, 14593-14598 (2004).
3. Weber, M. S. et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13, 935-943 (2007).
4. Kim, H. J. et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol. Baltim. Md. 1950 172, 7144-7153 (2004).
5. Jackson LJ, Selva S, Niedzielko T, Vollmer T B Cell Receptor Recognition of Glatiramer Acetate is Required for Efficacy through Antigen Presentation and Cytokine Production. J. Clin. Cell Immunol. 5: 185. doi:10.4172/2155-9899.1000185 (2014).
6. Burger, D. et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. 106, 4355-4359 (2009).
7. Gross, R. et al. Population structure and HLA DRB1∗1501 in the response of subjects with multiple sclerosis to first-line treatments. J. Neuroimmunol. 233, 168-174 (2011).
8. Weber, M. S. et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain J. Neurol. 127, 1370-1378 (2004).
9. Pul, R. et al. Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients. PLoS ONE 7, e51867 (2012).
10. Li, Q., Milo, R., Panitch, H., Swoveland, P. & Bever, C. T. Glatiramer acetate blocks the activation of THP-1 cells by interferongamma. Eur. J. Pharmacol. 342, 303-310 (1998).
11. Towfic, F. et al. Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic. PLoS ONE 9, e83757 (2014).
12. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 1-25 (2004).
13. Comi, G. & Moiola, L. Glatiramer acetate. Neurol. Barc. Spain 17, 244-258 (2002).
14. Rizvi, S. A., Kim, E. & Moodie, J. Glatiramer in the treatment of multiple sclerosis. Int. J. Nanomedicine 1, 283-289 (2006).
15. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1-13 (2009).
16. Sim, F. J. et al. CD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells. Nat. Biotechnol. 29, 934-941 (2011).
17. Vieira, P. L., Heystek, H. C., Wormmeester, J., Wierenga, E. A. & Kapsenberg, M. L. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. Baltim. Md 1950 170, 4483-4488 (2003).
18. Thamilarasan, M. et al. Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients. J. Neuroinflammation 10, 126 (2013).
19. Glass, W. G. et al. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J. Immunol. Baltim. Md. 1950 172, 4018-4025 (2004).
20. Allie, R., Hu, L., Mullen, K. M., Dhib-Jalbut, S. & Calabresi, P. A. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch. Neurol. 62, 889-894 (2005).
21. Mahad, D. et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain J. Neurol. 129, 212-223 (2006).
22. Rosenberg, G. A. Matrix metalloproteinases biomarkers in multiple sclerosis. The Lancet. 365, 1291-1293 (2005).
23. Christensen, J. R. et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult. Scler. J. 19, 877-884 (2013).
24. Kouwenhoven, M. et al. Monocyte-derived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis. J. Neuroimmunol. 126, 161-171 (2002).
25. Waubant, E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis. Markers 22, 235-244 (2006).
26. Milward, E. et al. Cleavage of myelin associated glycoprotein by matrix metalloproteinases. J. Neuroimmunol. 193, 140-148 (2008).
27. Knop, M. et al. Glatiramer Acetate Induced Intracellular Transgelin-2 Elevation Reduces MMP-9 Expression in Human Peripheral Blood Mononuclear Cells. Neurology 80, P05.147 (2013).
28. Parks, W. C., Wilson, C. L. & Lopez-Boado, Y. S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617-629 (2004).
29. Antonelli, A. et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13, 272-280 (2014).
30. Peperzak, V. et al. CD8+T cells produce the chemokine CXCL10 in response to CD27/CD70 costimulation to promote generation of the CD8+effector T cell pool. J. Immunol. Baltim. Md. 1950 191, 3025-3036 (2013).
31. Aderem, A. & Ulevitch, R. J. Toll-like receptors in the induction of the innate immune response. Nature 406, 782-787 (2000).
32. Baumann, C. L. et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J. Exp. Med. 207, 2689-2701 (2010).
33. Natarajan, C., Yao, S.-Y., Zhang, F. & Sriram, S. Activation of NOD2/RIPK2 pathway induces mitochondrial injury to oligodendrocyte precursor cells in vitro and CNS demyelination in vivo. J. Neuroimmunol. 265, 51-60 (2013).
34. Hedegaard, C. J., Enevold, C., Sellebjerg, F., Bendtzen, K. & Nielsen, C. H. Variation in NOD2 Augments Th2- and Th17 Responses to Myelin Basic Protein in Multiple Sclerosis. PLoS ONE 6, e20253 (2011).
35. Mycko, M. P., Kwinkowski, M., Tronczynska, E., Szymanska, B. & Selmaj, K. W. Multiple sclerosis: the increased frequency of the ICAM-1 exon 6 gene point mutation genetic type K469. Ann. Neurol. 44, 70-75 (1998).
36. Bullard, D. C. et al. Intercellular Adhesion Molecule-1 Expression Is Required on Multiple Cell Types for the Development of Experimental Autoimmune Encephalomyelitis. J. Immunol. 178, 851-857 (2007).
37. Sellner, J. et al. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis: Effect of GA on adhesion molecules in MS. Clin. Exp. Immunol. 173, 381-389 (2013).
38. Bertrand, M. J. M. et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30, 789-801 (2009).
39. Labbe, K., McIntire, C. R., Doiron, K., Leblanc, P. M. & Saleh, M. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity 35, 897-907 (2011).
40. Hebb, A. L. O. et al. Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Mult. Scler. Houndmills Basingstoke Engl. 14, 577-594 (2008).
41. Tseng, P.-H. et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat. Immunol. 11, 70-75 (2010).
42. Kearney, C. J. et al. Inhibitor of Apoptosis Proteins (IAPs) and Their Antagonists Regulate Spontaneous and Tumor Necrosis Factor (TNF)-induced Proinflammatory Cytokine and Chemokine Production. J. Biol. Chem. 288, 4878-4890 (2013).
43. Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29 (2000).
44. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30 (2000).
45. Zanin-Zhorov, A. et al. Heat shock protein 60 enhances CD4+CD25+regulatory T cell function via innate TLR2 signaling. J. Clin. Invest. 116, 2022-2032 (2006).
46. Qin, H. et al. Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc. Natl. Acad. Sci. 109, 5004-5009 (2012).
47. Vandenbroeck, K. et al. A cytokine gene screen uncovers SOCS1 as genetic risk factor for multiple sclerosis. Genes Immun. 13, 21-28 (2012).
48. Chiang, M.-F. et al. Inducible deletion of the Blimp-1 gene in adult epidermis causes granulocyte-dominated chronic skin inflammation in mice. Proc. Natl. Acad. Sci. 110, 6476-6481 (2013).
49. Cretney, E. et al. The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat. Immunol. 12, 304-311 (2011).
50. Bakshi, S. et al. Gene expression analysis reveals functional pathways of glatiramer acetate activation. Expert Opin. Ther. Targets 17, 351-362 (2013).
51. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostat. Oxf. Engl. 8, 118-127 (2007).
52. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882-883 (2012).